Equity

Merck & Co.·Balance Sheet Statement·15 metrics

Breakdown

Metric	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Total liabilities and stockholders' equity	$112.6B	$117.5B	$117.1B	$115.1B	$117.5B	$129.5B	$136.9B	$128.7B
Retained earnings	$60.2B	$61.4B	$63.1B	$66.1B	$68.5B	$72.2B	$73.1B	$66.7B
Treasury stock	$57.4B	$57.8B	$58.3B	$59.4B	$60.5B	$61.8B	$63.0B	$63.7B
Total stockholders' equity	$43.6B	$44.5B	$46.3B	$48.3B	$49.0B	$51.9B	$52.6B	$45.9B
Additional paid-in capital	$44.4B	$44.5B	$44.7B	$44.8B	$44.6B	$44.8B	$45.0B	$45.2B
Accumulated other comprehensive income (loss)	-$5.4B	-$5.4B	-$4.9B	-$5.0B	-$5.4B	-$5.2B	-$4.3B	-$4.1B
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$1.8B	$1.8B	$1.8B	$1.8B	$1.8B	$1.8B	$1.8B	$1.8B
Shares Outstanding	—	—	$249.0M	—	—	—	$275.0M	—
Convertible Preferred Stock Authorized Shares	—	—	20M	—	—	—	20M	—
Cumulative Gross Losses and Impairments	—	—	$531.0M	—	—	—	$531.0M	—
Number of Exercisable Options	—	—	$241.0M	—	—	—	$244.0M	—
Number of Vested and Expected to Vest Options	—	—	$249.0M	—	—	—	$272.0M	—
Shares Reserved for Future Issuance Under Stock Plans	—	—	75M	—	—	—	66M	—
Weighted Average Exercise Price of Outstanding Options	—	—	$86.04	—	—	—	$87.95	—
Weighted Average Exercise Price of Vested and Expected to Vest Options	—	—	$85.10	—	—	—	$87.73	—